MLYS Filings — Mineralys Therapeutics, Inc. - FilingSpy
MLYS
Mineralys Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing treatments for high blood pressure and related heart and kidney conditions driven by an excess of aldosterone, a hormone that regulates the body's mineral and fluid balance. Its lead medicine, lorundrostat, is an oral pill designed to curb aldosterone at its source for people whose hypertension won't stay controlled with standard drugs. Founded in 2019 by physician-venture capitalist BT Slingsby and based outside Philadelphia, the company originally launched under the name Catalys SC1 before renaming itself Mineralys in 2020—a nod to the "mineral" hormones it targets. It licensed lorundrostat from Japan's Mitsubishi Tanabe Pharma and went public in 2023.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: +8.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.